Mayne Pharma CEO Steps Down Amid $475m Metrics Contract Services Sale
CEO’s Departure Marks Turning Point For Mayne Pharma
Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.
You may also be interested in...
Gloomy First Half Results For Mayne
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market
Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO
Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.